

John R Ussher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2190855/publications.pdf>

Version: 2024-02-01

78
papers

7,975
citations

101543

36
h-index

74163

75
g-index

79
all docs

79
docs citations

79
times ranked

11995
citing authors

#	ARTICLE	IF	CITATIONS
1	Myocardial Fatty Acid Metabolism in Health and Disease. <i>Physiological Reviews</i> , 2010, 90, 207-258.	28.8	1,643
2	Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to Skeletal Muscle Insulin Resistance. <i>Cell Metabolism</i> , 2008, 7, 45-56.	16.2	1,618
3	Cardiovascular Biology of the Incretin System. <i>Endocrine Reviews</i> , 2012, 33, 187-215.	20.1	468
4	Cardiovascular Actions of Incretin-Based Therapies. <i>Circulation Research</i> , 2014, 114, 1788-1803.	4.5	301
5	Targeting fatty acid and carbohydrate oxidation – A novel therapeutic intervention in the ischemic and failing heart. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 1333-1350.	4.1	298
6	Inhibition of De Novo Ceramide Synthesis Reverses Diet-Induced Insulin Resistance and Enhances Whole-Body Oxygen Consumption. <i>Diabetes</i> , 2010, 59, 2453-2464.	0.6	296
7	The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2850-2870.	2.8	259
8	Cardiac Insulin-Resistance and Decreased Mitochondrial Energy Production Precede the Development of Systolic Heart Failure After Pressure-Overload Hypertrophy. <i>Circulation: Heart Failure</i> , 2013, 6, 1039-1048.	3.9	196
9	Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. <i>Cardiovascular Research</i> , 2012, 94, 359-369.	3.8	154
10	Gut microbiota metabolism of l-carnitine and cardiovascular risk. <i>Atherosclerosis</i> , 2013, 231, 456-461.	0.8	152
11	Lipotoxicity in obesity and diabetes-related cardiac dysfunction. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 1555-1568.	2.4	125
12	Insulin-Stimulated Cardiac Glucose Oxidation Is Increased in High-Fat Diet-Induced Obese Mice Lacking Malonyl CoA Decarboxylase. <i>Diabetes</i> , 2009, 58, 1766-1775.	0.6	116
13	Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. <i>Cardiovascular Research</i> , 2019, 115, 1606-1616.	3.8	114
14	TCF1 links GIPR signaling to the control of beta cell function and survival. <i>Nature Medicine</i> , 2016, 22, 84-90.	30.7	108
15	Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. <i>Cardiovascular Research</i> , 2011, 89, 148-156.	3.8	105
16	Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. <i>Molecular Metabolism</i> , 2014, 3, 507-517.	6.5	102
17	Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. <i>Cardiovascular Diabetology</i> , 2019, 18, 86.	6.8	102
18	Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction. <i>Cardiovascular Diabetology</i> , 2019, 18, 1.	6.8	98

#	ARTICLE	IF	CITATIONS
19	Evolving Concepts of Myocardial Energy Metabolism. <i>Circulation Research</i> , 2016, 119, 1173-1176.	4.5	90
20	Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. <i>Cardiovascular Research</i> , 2014, 101, 30-38.	3.8	83
21	Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat Fed Diabetic Mice. <i>Diabetes</i> , 2016, 65, 742-754.	0.6	82
22	The malonyl CoA axis as a potential target for treating ischaemic heart disease. <i>Cardiovascular Research</i> , 2008, 79, 259-268.	3.8	79
23	Targeting ceramide metabolism in obesity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E423-E435.	3.5	79
24	Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. <i>Cell Metabolism</i> , 2017, 25, 152-165.	16.2	79
25	Pyridine Nucleotide Regulation of Cardiac Intermediary Metabolism. <i>Circulation Research</i> , 2012, 111, 628-641.	4.5	68
26	The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. <i>Molecular Metabolism</i> , 2017, 6, 1339-1349.	6.5	63
27	Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. <i>Basic Research in Cardiology</i> , 2009, 104, 203-210.	5.9	57
28	Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. <i>Cell Metabolism</i> , 2018, 27, 450-460.e6.	16.2	56
29	Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite. <i>Pharmacological Reviews</i> , 2010, 62, 237-264.	16.0	55
30	Ketones can become the major fuel source for the heart but do not increase cardiac efficiency. <i>Cardiovascular Research</i> , 2021, 117, 1178-1187.	3.8	55
31	Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. <i>Molecular Metabolism</i> , 2015, 4, 132-143.	6.5	54
32	Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	51
33	Glucagon-like peptide-1 receptor action in the vasculature. <i>Peptides</i> , 2019, 111, 26-32.	2.4	50
34	Inhibition of Serine Palmitoyl Transferase I Reduces Cardiac Ceramide Levels and Increases Glycolysis Rates following Diet-Induced Insulin Resistance. <i>PLoS ONE</i> , 2012, 7, e37703.	2.5	44
35	The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 345-358.	1.5	44
36	FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H479-H490.	3.2	44

#	ARTICLE	IF	CITATIONS
37	Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2019, 4, 385-400.	4.1	37
38	Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation. <i>Cell Metabolism</i> , 2020, 31, 909-919.e8.	16.2	37
39	Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway. <i>Molecular Metabolism</i> , 2017, 6, 503-511.	6.5	33
40	The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2021, 37, 140-150.	1.7	33
41	Trimetazidine Therapy Prevents Obesity-Induced Cardiomyopathy in Mice. <i>Canadian Journal of Cardiology</i> , 2014, 30, 940-944.	1.7	26
42	FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity. <i>Cell Reports</i> , 2021, 35, 108935.	6.4	26
43	Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. <i>Clinical Lipidology</i> , 2009, 4, 379-389.	0.4	24
44	Role of the atypical protein kinase C η in regulation of 5 α -AMP-activated protein kinase in cardiac and skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E349-E357.	3.5	21
45	Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 570421.	2.8	20
46	GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue. <i>Diabetes</i> , 2022, 71, 1115-1127.	0.6	20
47	Guidelines on models of diabetic heart disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H176-H200.	3.2	20
48	Metabolic, structural and biochemical changes in diabetes and the development of heart failure. <i>Diabetologia</i> , 2022, 65, 411-423.	6.3	19
49	The impact of current and novel anti-diabetic therapies on cardiovascular risk. <i>Future Cardiology</i> , 2012, 8, 895-912.	1.2	18
50	A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactions. <i>Bioorganic Chemistry</i> , 2019, 93, 103269.	4.1	18
51	Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154871.	3.4	18
52	Treatment with the 3-Ketoacyl-CoA Thiolase Inhibitor Trimetazidine Does Not Exacerbate Whole-Body Insulin Resistance in Obese Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 487-496.	2.5	17
53	Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. <i>Peptides</i> , 2018, 100, 94-100.	2.4	17
54	SP1-independent inhibition of FOXM1 by modified thiazolidinediones. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112902.	5.5	16

#	ARTICLE	IF	CITATIONS
55	The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity. <i>JCI Insight</i> , 2019, 4, .	5.0	14
56	Pyruvate Dehydrogenase as a Therapeutic Target for Nonalcoholic Fatty Liver Disease. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 582-588.	4.9	14
57	Genetic and Pharmacological Inhibition of Malonyl CoA Decarboxylase Does Not Exacerbate Age-Related Insulin Resistance in Mice. <i>Diabetes</i> , 2016, 65, 1883-1891.	0.6	13
58	Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. <i>Diabetes</i> , 2022, 71, 173-183.	0.6	13
59	Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 235-245.	1.9	11
60	<sc>L</sc> Citrulline supplementation improves glucose and exercise tolerance in obese male mice. <i>Experimental Physiology</i> , 2020, 105, 270-281.	2.0	11
61	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 603247.	2.8	11
62	Accumulation of ceramide in slow-twitch muscle contributes to the development of insulin resistance in the obese JCR:LA-cp rat. <i>Experimental Physiology</i> , 2015, 100, 730-741.	2.0	10
63	Cardiovascular biology of the GIP receptor. <i>Peptides</i> , 2020, 125, 170228.	2.4	10
64	Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H2255-H2269.	3.2	9
65	Skeletal muscle-specific Cre recombinase expression, controlled by the human β -skeletal actin promoter, improves glucose tolerance in mice fed a high-fat diet. <i>Diabetologia</i> , 2018, 61, 1849-1855.	6.3	8
66	Dietary-Induced Obesity, Hepatic Cytochrome P450, and Lidocaine Metabolism: Comparative Effects of High-Fat Diets in Mice and Rats and Reversibility of Effects With Normalization of Diet. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1199-1210.	3.3	8
67	SNPs for Genes Encoding the Mitochondrial Proteins Sirtuin3 and Uncoupling Protein 2 Are Associated With Disease Severity, Type 2 Diabetes, and Outcomes in Patients With Pulmonary Arterial Hypertension and This Is Recapitulated in a New Mouse Model Lacking Both Genes. <i>Journal of the American Heart Association</i> , 2021, 10, e020451.	3.7	7
68	Deciphering ventricular GLP-1 action: time for a change of heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H1390-H1392.	3.2	6
69	Targeting MicroRNAs to Limit Myocardial Lipid Accumulation. <i>Circulation Research</i> , 2015, 116, 229-231.	4.5	5
70	Revisiting protein acetylation and myocardial fatty acid oxidation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H617-H619.	3.2	5
71	Female offspring born to obese and insulin-resistant dams are not at increased risk for obesity and metabolic dysfunction during early development. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 97-102.	1.4	4
72	Sugar-sweetened beverages and vascular function: food for thought. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H285-H288.	3.2	3

#	ARTICLE	IF	CITATIONS
73	An isoproteic cocoa butter-based ketogenic diet fails to improve glucose homeostasis and promote weight loss in obese mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2022, 323, E8-E20.	3.5	3
74	Incretin-based therapies for the failing heart. <i>Cardiovascular Endocrinology</i> , 2016, 5, 86-92.	0.8	1
75	Cardiovascular outcome in Atrial fibrillation in Type 2 diabetes: food for thought. <i>Future Cardiology</i> , 2021, 17, 407-410.	1.2	1
76	Decreased Maternal Cardiac Glucose Oxidation. <i>Circulation Research</i> , 2017, 121, 1299-1301.	4.5	0
77	The antianginal ranolazine does not confer beneficial actions against hepatic steatosis in male mice subjected to high-fat diet and streptozotocin induced type 2 diabetes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, , .	1.4	0
78	New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	0